ID   SU-DIPG-VI
AC   CVCL_IT40
AS   CVCL_IP15
SY   SU-DIPGVI; SUDIPGVI; SU-DIPG-6; DIPG 6; DIPG-6; DIPG6; SJHGG042550
DR   BTO; BTO:0005954
DR   cancercelllines; CVCL_IT40
DR   Wikidata; Q54970735
RX   PubMed=24777482;
RX   PubMed=25366336;
RX   PubMed=25939062;
RX   PubMed=28823557;
RX   PubMed=33319914;
RX   PubMed=34215733;
RX   PubMed=34732238;
WW   http://mckennaclairefoundation.org/
CC   Doubling time: 5.8 days (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062; PubMed=34732238).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=34732238).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu198Ter (c.592G>T); ClinVar=VCV000634704; Zygosity=Unspecified (PubMed=34732238).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Donor information: Established from a sample taken just after the death at age 7 of McKenna Wetzel. When McKenna died, the Wetzels donated to researchers at Stanford University the tissues that allowed this cell line to be derived. They also created the McKenna Claire Foundation's whose mission is to help cure pediatric brain cancer by raising awareness, increasing community involvement and funding research.
CC   Derived from site: In situ; Brainstem, pons; UBERON=UBERON_0000988.
ST   Source(s): PubMed=25939062; PubMed=28823557; PubMed=34732238
ST   Amelogenin: X
ST   CSF1PO: 9,10 (PubMed=28823557)
ST   CSF1PO: 10,11 (PubMed=25939062; PubMed=34732238)
ST   D13S317: 11
ST   D16S539: 8,13 (PubMed=25939062; PubMed=28823557)
ST   D16S539: 13 (PubMed=34732238)
ST   D21S11: 29,30,31 (PubMed=34732238)
ST   D21S11: 29,31 (PubMed=25939062; PubMed=28823557)
ST   D5S818: 10,12
ST   D7S820: 8,9
ST   TH01: 7,8
ST   TPOX: 8,11
ST   vWA: 17,18 (PubMed=25939062; PubMed=28823557)
ST   vWA: 18 (PubMed=34732238)
DI   NCIt; C94764; Diffuse intrinsic pontine glioma
DI   ORDO; Orphanet_497188; Diffuse intrinsic pontine glioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   7Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 13
//
RX   PubMed=24777482; DOI=10.1007/s00401-014-1272-4; PMCID=PMC4135053;
RA   Caretti V., Sewing A.C.P., Lagerweij T., Schellen P., Bugiani M.,
RA   Jansen M.H.A., van Vuurden D.G., Navis A.C., Horsman I., Vandertop W.P.,
RA   Noske D.P., Wesseling P., Kaspers G.J.L., Nazarian J., Vogel H.,
RA   Hulleman E., Monje M., Wurdinger T.;
RT   "Human pontine glioma cells can induce murine tumors.";
RL   Acta Neuropathol. 127:897-909(2014).
//
RX   PubMed=25366336; DOI=10.1093/neuonc/nou303; PMCID=PMC4482855;
RA   Green A.L., Ramkissoon S.H., McCauley D., Jones K., Perry J.A.,
RA   Hsu J.H.-R., Ramkissoon L.A., Maire C.L., Hubbell-Engler B., Knoff D.S.,
RA   Shacham S., Ligon K.L., Kung A.L.-J.;
RT   "Preclinical antitumor efficacy of selective exportin 1 inhibitors in
RT   glioblastoma.";
RL   Neuro-oncol. 17:697-707(2015).
//
RX   PubMed=25939062; DOI=10.1038/nm.3855; PMCID=PMC4862411;
RA   Grasso C.S., Tang Y.-J., Truffaux N., Berlow N.E., Liu L.-N.,
RA   Debily M.-A., Quist M.J., Davis L.E., Huang E.C., Woo P.J.,
RA   Ponnuswami A., Chen S., Johung T.B., Sun W.-C., Kogiso M., Du Y.-C.,
RA   Qi L., Huang Y.-L., Hutt-Cabezas M., Warren K.E., Le Dret L.,
RA   Meltzer P.S., Mao H., Quezado M., van Vuurden D.G., Abraham J.,
RA   Fouladi M., Svalina M.N., Wang N., Hawkins C., Nazarian J.,
RA   Alonso M.M., Raabe E.H., Hulleman E., Spellman P.T., Li X.-N.,
RA   Keller C., Pal R., Grill J., Monje M.;
RT   "Functionally defined therapeutic targets in diffuse intrinsic pontine
RT   glioma.";
RL   Nat. Med. 21:555-559(2015).
//
RX   PubMed=28823557; DOI=10.1016/j.cell.2017.07.016; PMCID=PMC5587159;
RA   Qin E.Y., Cooper D.D., Abbott K.L., Lennon J., Nagaraja S., Mackay A.,
RA   Jones C., Vogel H., Jackson P.K., Monje M.;
RT   "Neural precursor-derived pleiotrophin mediates subventricular zone
RT   invasion by glioma.";
RL   Cell 170:845-859.e19(2017).
//
RX   PubMed=33319914; DOI=10.1093/gigascience/giaa136; PMCID=PMC7736793;
RA   Sanders L.M., Cheney A., Seninge L., van den Bout A., Chen M.,
RA   Beale H.C., Kephart E.T., Pfeil J., Learned K., Lyle A.G., Bjork I.,
RA   Haussler D., Salama S.R., Vaske O.M.;
RT   "Identification of a differentiation stall in epithelial mesenchymal
RT   transition in histone H3-mutant diffuse midline glioma.";
RL   GigaScience 9:giaa136.1-giaa136.14(2020).
//
RX   PubMed=34215733; DOI=10.1038/s41467-021-24168-8; PMCID=PMC8253809;
RA   He C., Xu K., Zhu X.-Y., Dunphy P.S., Gudenas B., Lin W.-W., Twarog N.,
RA   Hover L.D., Kwon C.-H., Kasper L.H., Zhang J.-Y., Li X.-Y., Dalton J.,
RA   Jonchere B., Mercer K.S., Currier D.G., Caufield W., Wang Y.-Z., Xie J.,
RA   Broniscer A., Wetmore C., Upadhyaya S.A., Qaddoumi I., Klimo P.,
RA   Boop F., Gajjar A., Zhang J.-H., Orr B.A., Robinson G.W., Monje M.,
RA   Freeman B.B. 3rd, Roussel M.F., Northcott P.A., Chen T.-S., Rankovic Z.,
RA   Wu G., Chiang J.C.-H., Tinkle C.L., Shelat A.A., Baker S.J.;
RT   "Patient-derived models recapitulate heterogeneity of molecular
RT   signatures and drug response in pediatric high-grade glioma.";
RL   Nat. Commun. 12:4089.1-4089.17(2021).
//
RX   PubMed=34732238; DOI=10.1186/s40478-021-01270-y; PMCID=PMC8565061;
RA   Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H.,
RA   Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.;
RT   "TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are
RT   sensitive to a MDM2 antagonist.";
RL   Acta Neuropathol. Commun. 9:178.1-178.12(2021).
//